Fig. 1.

Proportions (%) of patients with four and fewer than four PPFs achieving ACR20/50/70 response over time for A ACR20 B ACR50 C ACR70. All treatment groups also received methotrexate. For ACR20, response rates with FIL200 and FIL100 were significantly different (P < 0.05) versus PBO at weeks 2–24, except for FIL100 at week 14, in the four-PPF subgroup and at every timepoint in the fewer-than-four-PPF subgroup. Response rates with FIL200 were significantly different (P < 0.05) versus ADA at weeks 30, 44, and 52 among patients with four PPFs, while FIL100 was not significantly different from ADA at any timepoint. Among patients with fewer than four PPFs, response rates among both filgotinib groups were similar to those of ADA. For ACR50, response rates with FIL200 and FIL100 were significantly different (P < 0.05) versus PBO at every timepoint in the four-PPF subgroup and in the fewer-than-four-PPF subgroup. For ACR70, response rates with FIL200 were significantly different (P < 0.05) versus PBO at every timepoint in both subgroups except at week 2 among patients with four PPFs. FIL100 was significantly different from PBO at every timepoint except weeks 2 and 4 in both subgroups. Response rates with FIL were not significantly different versus ADA at weeks 26–52 in either subgroup. ACR20/50/70 American College of Rheumatology 20%, 50%, and 70% improvement; ADA adalimumab; BL baseline; FIL100 filgotinib 100 mg; FIL200 filgotinib 200 mg; PBO placebo; PPF poor prognostic factor